Physician profile
Emily Mintz
NPI 1194978254
$6,880.22
in general payments reported to CMS, 2019-2025
27 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $117 · 2021: $461 · 2022: $876 · 2023: $1,398 · 2024: $1,555 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,609 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.75 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.01 | 2019-2025 | |
| Genzyme Corporation | $910.20 | 2019-2025 | |
| Amgen INC. | $698.41 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $640.88 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $628.65 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $444.34 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Regeneron Healthcare Solutions, INC. | $437.31 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $296.67 | 2019-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $235.63 | 2023-2025 | Ilumya |
| Incyte Corporation | $217.21 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $190.52 | 2019-2025 | |
| Lilly USA, LLC | $187.50 | 2019-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $175.60 | 2023-2025 | Sotyktu |
| Revance Therapeutics, INC. | $115.83 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.15 | 2019-2024 | Cabtreo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $88.65 | 2019 | |
| Pfizer INC. | $76.20 | 2019-2021 | |
| Ucb, INC. | $67.23 | 2025 | Bimzelx |
| Almirall LLC | $61.04 | 2019-2023 | Seysara |
| Allergan, INC. | $51.66 | 2019-2020 | |
| Journey Medical Corporation | $50.28 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $34.22 | 2025 | |
| Botanix Sb INC | $33.24 | 2025 | Sofdra |
| Organon LLC | $32.00 | 2025 | |
| Epi Health, LLC | $26.35 | 2021 | |
| Merz North America, INC. | $25.00 | 2020 | |
| Verrica Pharmaceuticals INC. | $17.44 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.